Helicobacter pylori infection: Anything new should we know?

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL.2, 2004, Pages 31-41

  Basset, C ^a   Holton, J ^a   Gatta, L ^b   Ricci, C ^b   Bernabucci, V ^b   Liuzzi, G ^b   Vaira, D ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIGEN; CAGA PROTEIN; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE; VACUOLATING TOXIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; ERADICATION THERAPY; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMAN GENOME; INFECTION CONTROL; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROTEOMICS; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH EPITHELIUM; STOMACH INJURY; SYSTEMATIC REVIEW;

EID: 4544333193     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02040.x     Document Type: Conference Paper

References (74)

1. Sheu BS, Sheu SM, Yang HB, Huang AH, Wu JJ. Host gastric lewis expression determines the bacterial density of Helicobacter pylon in babA2 genotype infection. Gut 2003; 52: 927-3.
2. Lai YC, Wang TH, Huang SH, et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol 2003; 9: 1537-40.
3. Oliveira AG, Santos A, Guerra JB, et al. BabA2 and cagA positive Helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil. J Clin Microbiol 2003; 41: 3964-6.
4. Nilsson C, Sillen A, Eriksson L, et al. Correlation between cag pathogenicity island composition and Helicobacter pylori associated gastroduodenal disease. Infect Immun 2003; 71: 6573-81.
5. Owen RJ, Sharp SI, Chisholm SA, Rijpkema S. Identification of cagA tyrosine phosphorylation DNA motifs in Helicobacter pylori isolates from peptic ulcer patients by novel PCR restriction fragment length polymorphism and real time fluorescent PCR assays. J Clin Microbiol 2003; 41: 3112-8.
6. Xu C, Li ZS, Tu ZX, Xu GM, Gong YF, Man XH. Distribution of gagG gene in Helicobacter pylori isolates from Chinese patients with different gastroduodenal diseases and its clinical and pathological significance. World J Gastroenterol 2003; 9: 2258-60.
7. Nakayama M, Kimura M, Wada A, et al. Helicobacter pylori vacA activates the p38 activating transcription factor 2 mediated signal pathway in AZ 521 cells, J Biol Chem 2004; 279: 7024-8.
8. Cho SJ, Kang NS, Park SY, Kim BO, Rhee DK, Pyo S. Induction of apoptosis and expression of apoptosis related genes in human epithelial carcinoma cells by Helicobacter pylori vacA toxin. Toxicon 2003; 42: 601-11.
9. Su B, Ceponis PJ, Sherman PM. Cytoskeletal rearrangements in gastric epithelial cells in response to Helicobacter pylori infection. J Med Micro 2003; 52: 861-7.
10. Seo JH, Lim JW, Kim H, Kim KH. Helicobacter pylori in a Korean isolate activates mitogen activated protein kinases AP-1 and Nkkappa B and induces chemokine expression in gastric epithelial AGS cells. Lab Invest 2004; 84: 49-62.
11. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
12. Garcia-Gonzalez MA, Lanas A, Savelkoul PH, et al. Associated interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 2003; 134: 525-31.
13. Rad R, Prinz C, Neu B, et al. Synergistic effect of Helicobacter pylori virulence factors and interleukin 1 polymorphisms for the development of severe histological changes in the gastric mucosa. J Infect Dis 2003; 188; 272-81.
14. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin 10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003; 104: 617-23.
15. Fukui H, Franceschi F, Penland RL, et al. Effects of Helicobacter pylori infection on the link between regenerating gene expression and serum gastrin levels in Mongolian gerbils. Lab Invest 2003; 83: 1777-86.
16. Konturek SJ, Bielanski W, Plonka M, et al. Helicobacter pylori non steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal disease. Scand J Gastroenterol 2003; 38: 923-30.
17. Regula J, Hennig E, Burzykowski T, et al. Multivariate analysis of risk factors for the development of duodenal ulcersin Helicobacter pylori-infected patients. Digestion 2003; 67: 25-31.
18. Vaira D, Vakil N, Rugge M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymtomatic subjects. Gut 2003; 52: 1543-7.
19. Ohksua T, Okayasu I, Miwa H, Ohtaka K, Endo S, Sato N. Helicobacter pylori infection induces duodenitis and superficial duodenal ulcer in Mongolian gerbils. Gut 2003; 52: 797-803.
20. Leodolter A, Wolle K, Peitz U, et al. Helicobacter pylori genotypes and expression of gastritis in erosive gastro-oesophageal reflux disease. Scand J Gastroenterol 2003; 38: 495-502.
21. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003; 98: 1462-70.
22. Basset C, Holton J, Bazeos A, Vaira D, Bloom S. Presence of Helicobacter and enterotoxigenic Bacteroides fragilis in patients with inflammatory bowel disease [Abstract]. Gut 2004; 53 (Suppl. III): A95.
23. Bell SJ, Chisholm SA, Owen RJ, Borriello SP, Kamm MA. Evaluation of Helicobacter species in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 481-6.
24. Diaz C, O'Callaghan CJ, Khan A, Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venerol 2003; 83: 282-6.
25. Migneco A, Ojetti V, Specchia L, et al. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter 2003; 8: 585-9.
26. Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, Marz W. Effect of Helicobacter pylori eradication on high density lipoprotein cholesterol. Am J Cardiol 2004; 93: 219-20.
27. Jaing TH Yang CP Huang IJ Chiu CH Chang KW. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003; 92: 1153-7.
28. Zullo A Hassan C Lorenzetti R Winn S Morini S. A clinical practical viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
29. Gatta L Vakil N Ricci C, et al. A rapid low-dose 13C-urea tablet for the detection of Helicobacter pylori infection before and after treatment. Aliment Pharmacol Ther 2003; 17: 793-8.
30. Wu IC, Ke HL, Lo YC, et al. Evaluation of a newly developed office based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 2003; 50: 1761-5.
31. Gatta L, Perna F, Ricci C, Tampieri A, Miglioli M, Vaira D. New rapid One Step Stool Antigen Test for diagnosing and monitoring Helicobacter pylori infection. Helicobacter 2003; 8: 1703.
32. Leodolter A, Vaira D, Bazzoli F, et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18: 927-31.
33. Krah A, Miehlke S, Pleissner KP, et al. Identification of candidate antigens for serologic detection of Helicobacter pylori infected patients with gastric carcinoma. Int J Cancer 2004; 108: 456-63.
34. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-6.
35. Thijs JC, Arents NL, Van Zwet AA, Kleibeuker JH. Dyspepsia management in primary care. Scand J Gastroenterol 2003; 239: 44-50.
36. Chey WD, Moayyedi P. Review article. uninvestigated dyspepsia and non-ulcer dyspepsia - the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther Suppl 2004; I: 1-18.
37. Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL. FROSCH Study Group. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003; 52: 40-6.
38. Heikkinen M, Farkkila M. What is the long term outcome of the different subgroups of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 223-9.
39. Malfertheiner P, Mégraud F, Morain CO, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
40. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330-8.
41. Janssen MJR, Van Oijen AHAM, Verbeek ALM, Jansen JBMJ. de Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitromidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
42. Maconi G, Russo A, Imbesi V, Cucino C, Bianchi Porro G. Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? Digest Liver Dis 2000; 32: 275-80.
43. Bigard MA, Delchier JC, Riachi G, et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-8.
44. Deltenre M, Jonas C, Van Gossum M, Buser M, Otero J, De Koster E. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol 1997; 7 (Suppl. 1): S39-S44.
45. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 483-7.
46. Wong BCY, Chang FY, Abid S, et al. Triple therapy with clarithromycin, omeprazole, and amoxycillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 1529-35.
47. Vakil N, McSorley D, Hahn B, Ciociola A, Webb D. Clarithromycin resistant Helicobacter pylori in the United States. Am J Gastroenterol 1998; 93: 1432-5.
48. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
49. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
50. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxycillin in patients with peptic ulcer disease; results of two double-blind, randomized studies. Helicobacter 2003; 8: 626-42.
51. Malfertheiner P, Kirchner T, Kist M, et al. Advanced Gastric Ulcer Study Group Helicobacter pylori eradication and gastric ulcer healing - comparison of three pantoprazole based triple therapies. Aliment Pharmacol Ther 2003; 17: 1125-35.
52. Boixeda D, Martin De Argua C, Bermejo F, Lopez Sanroman A, Hernandez Ranz F, Garcia Plaza A. Seven day proton pump inhibitor amoxycillin and clarithromycin triple therapy: factors that influence Helicobacter pylori eradication success. Rev Esp Enferm Dig 2003; 95: 206-9.
53. Laine L, Fennerty MB, Hosato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effects of antibiotic resistance: results of three US multicenter, double blind trials. Am J Gastroenterol 2000; 95: 3393-8.
54. Van Zanten V, Machado S, Lee J. One week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1381-7.
55. Fakheri H, Marat S, Hosseini V, Malekzadeh R. Low dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 89-93.
56. Ojetti V, Migneco A, Zocco MA, Nista EC, Gasbarrini G, Gasbarrini A. Beta-lactamase inhibitor enhances Helicobacter eradication rate. J Intern Med 2004; 255: 125-9.
57. Watanabe Y Aoyama N Shirasaka D, et al. Levofloxacin based triple therapy as a second line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 711-5.
58. Furuta T, Shirai N, Xiao F, et al. High dose rabeprazole/amoxycillin therapy as a second line regimen after failure to eradicate H. pylori by triple therapy with the usual dose of a proton pump inhibitor clarithromycin and amoxycillin. Hepatogastroenterology 2003; 50: 2274-8.
59. Gatta L, Ricci C, Zullo A, et al. High eradication rate with a rescue levofloxacin based treatment for Helicobacter pylori. Gastroenterology 2004; 126: A74.
60. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol 2003; 43: 1316-23.
61. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98; 1010-5.
62. Take S, Mizuno M, Ishiki K, et al. Interleukin 1 beta genetic polymorphism influences the effect of cytochrome P2C19 genotype on the cure rate of 1 week triple therapy for Helicobacter pylori infecton. Am J Gastroenterol 2003; 98: 2403-8.
63. Haristoy X, Angioi-Duprez K, Duprez A, Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother 2003; 47: 3982-4.
64. Bhamarapravati S, Pentland SL, Mahady GB. Extracts of spice and food plants from Thai traditional medicine inhibit the growth of the human carcinogen Helicobacter pylori. In Vivo 2003; 17: 541-4.
65. Bergonzelli GE, Donnicola D, Porta N, Corthesy-Theulaz IE. Essential oils as components of a diet based approach to management of Helicobacter infection. Antimicrob Agents Chemother 2003; 47: 3240-6.
66. Di Mario F, Aragona G, Dal Bo N, et al. A use of bovine lactoferrin for Helicobacter eradication. Dig Liver Dis 2003; 35: 706-10.
67. Chen M, Chen J, Liao W, et al. Immunisation with attenuated Salmonella typhimurium producing catalase in protection against gastric Helicobacter pylori infection in mice. Helicobacter 2003; 8: 631-25.
68. Raghavan S, Nystrom J, Fredriksson M, Holmgren J, Harandi AM. Orally administered CpG oligonucleotides induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonisation in a mouse model of Helicobacter pylori infection. Infect Immun 2003; 71: 7022.
69. Arkkila PE, Seppala K, Kosunen TU, et al. Eradication of Helicobacter pylori improves the healing rate reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer. Am J Gastroenterol 2003; 98: 2149-56.
70. Schilling D, Demel A, Nusse T, Weidmann E, Reimann JF. Helicobacter pylori infection does not affect the early rebleed rate in patients with peptic ulcer bleeding after successful endoscopic haemostasis: a prospective single centre trial. Endoscopy 2003; 35: 393-6.
71. Gisbert J, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz J. H. pylori eradication therapy vs antisecretory non-eradication therapy (with or without long term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2003; 4: CD004062.
72. Schilling D, Demel A, Adamek HE, Nusse T, Weidmann E, Riemann JF. A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis 2003; 35: 217-21.
73. Peitz U Leodolter A Kahl S, et al. Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003; 17: 1075-84.
74. Romero-Gomez M, Martinez-Delgado C, Hergueta P, et al. Three day intravenous triple therapy is not effective for the eradication of Helicobacter pylori in patients with bleeding gastroduodenal ulcers. Aliment Pharmacol Ther 2003; 18: 1023-1029.